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Methylene blue is an intravenously administered agent that may potentiate serotonin syndrome. The
usage of methylene blue to evaluate ureters for injuries and patency during urological surgeries is
recognized as common practice. However, there is no mention of serotonin syndrome caused by
methylene blue in urological literature or for urological surgery. We report the ﬁrst urological case in
order to raise awareness of the risk for serotonin toxicity with utilizing methylene blue.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Serotonin syndrome (SS) results from high levels of serotonin
within the nervous system causing a range of symptoms from mild
to life-threatening. Most commonly seen medications that may
induce SS include selective serotonin reuptake inhibitors (SSRIs) or
serotonin-norepinephrine reuptake inhibitors (SNRIs) in combina-
tion with monoamine oxidase inhibitors (MAOIs).1 The three hall-
mark signs of SS include altered mental status, hyperactive
automaticity, and abnormal neuromuscular function.1 Two com-
mon criteria used in literature are the Sternbach’s criteria and the
Hunter’s Serotonin Toxicity criteria (Table 1).Case presentation
A 74-year-old woman with past medical history notable for
Parkinson’s disease, depression, anxiety, and pelvic organ prolapse
presented with cystocele (Table 2). She was scheduled for repeat
cystocele repair, due to worsening of incontinence and pelvic organ
prolapse. Her current medications consisted of Ropinirole for her
restless leg syndrome, as well as Fluoxetine (SSRI) and Duloxetine
(SNRI) for depression and anxiety. At baseline, the patient was alert
and oriented with normal mental status.ine.edu (K. Kapadia).
Inc. This is an open access article uThe patient underwent general anesthesia (Table 3). There was
successful reduction of a large cystocele with cadaveric fascia
without any surgical complications. 100 mg of 1% MB was admin-
istered at the beginning of the procedure to rule out potential
vesicaleureteral injury. Cystoscopy did not demonstrate any in-
juries and blue-tinged ureteral jets were visualized from both
ureteral oriﬁces.
Approximately 1 h post-operatively the patient became agitated
and tachycardic to 108 bpm. She was unable to express herself and
had uncontrollable movements of all four limbs. She was given her
Parkinson’s medications, Stalevo and Ropinirole. Bladder scan
demonstrated 450 cc residual urine and a foley catheter was placed.
Urinalysis and urine culture were obtained. The patient was
transferred to the main hospital emergency room and neurology
was consulted.
Five hours post-operatively the patient’s heart rate remained
elevated along with a mild elevation in temperature (37.6 C). She
was nonverbal with hyperactive delirium. Labs demonstrated
elevated AST (44 IU/L) and CPK levels (556 IU/L); critically low lactic
acid (4.7 mmol/L); and leukocytosis (17.8 K/mL). She was started on
empiric antibiotics, IV ﬂuids, and benzodiazepines for agitation.
Head CAT scan and chest X-ray were normal. On neurologic exam,
the patient was obtunded and dysarthric with restlessness in all
extremities. Reﬂexes were normal and coordination was unable to
be assessed.
The patient was transferred to the medical intensive care unit.
She gradually improved with supportive care over the course of thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Diagnostic criteria for serotonin syndrome1
Sternbach’s criteria Hunter’s criteria
1. Patient on serotonergic agent
2. Absence of other causes or
etiologies
3. No current use of neuroleptic
agent
4. Presence of three of the
following:
 Mental status change (confu-
sion, hypomania, restlessness,
ataxia)
 Agitation
 Myoclonus
 Hyperreﬂexia
 Diaphoresis
 Shivering
 Tremor
 Diarrhea
 Incoordination
 Fever
1. Patient on serotonergic agent
2. Presence of any of the following:
 Spontaneous clonus
 Inducible clonus AND agita-
tion OR diaphoresis
 Ocular clonus AND agitation
OR diaphoresis
 Tremor AND hyperreﬂexia
 Hypertonic AND hyperther-
mia (>38 C) AND ocular
clonus OR inducible clonus
Table 3
General anesthesia course during cystocele repair
Midazolam 1 mg/mL INJ IV Push 1 mg
Fentanyl 50 mcg/mL IV Pusha 25 mcg
Propofol 10 mg/mL INJ IV Push 150 mg
Propofol 20 mg/mL INJ Continuous IV 252 mg
Rocuronium 50 mg/5 mL INJ IV Push 20 mg
Dexamethasone 4 mg/mL INJ IV Push 4 mg
ePHEDrine 5 mg/1 mL NS OR SYRINGE IV Push 10 mg
Ondansetron 2 mg/mL 2 mL INJ IV Push 4 mg
Acetaminophen (OFIRMEV) 10 mg/mL INJ IVPB 1 g
Methylene blue 1% 10 mL INJ IV Push 10 mL
Neostigmine 1:1000 INJ IV Push 2 mg
Glycopyrrolate 0.2 mg/mL INJ IV Push 0.4 mg
a Warning for serotonin syndrome.
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was presumed to be elevated from agitation. Suspicion for SS was
based on the patient being on a serotonergic agent and presentation
of altered mental status, agitation, diaphoresis, hyperthermia, and
hypertonia. This met Sternbach’s criteria for SS (Table 1). Benzodi-
azepines were discontinued and all anti-psychotic medications
were held.
The following day her mental status improved. Her fever and
leukocytosis resolved. Urine culture was negative. Foley catheter
was removed and the patient was able to void without difﬁculty.
She was downgraded to regular ﬂoor bed and the remainder of theTable 2
Patient history
Past medical history Past surgical history Home medications
 Anxiety
 Asthma
 Cystocele
 Depression
 Gastroesophageal
Reﬂux Disease
(GERD)
 Gout
 Hypothyroidism
 Hypertension
 Hyperlipidemia
 Incontinence (urinary,
stress, urge)
 Nocturia
 Obesity
 Osteoporosis
 Parkinson’s
 Obstructive sleep apnea
 Uterovaginal
prolapse
 Cystocele repair
 Cystoscopy
 Interstim
 Hip replacement
 Hiatal hernia repair
 Abdominoplasty
 Knee replacement
 Total abdominal
hysterectomy
 Tonsillectomy/
adenoidectomy
 Allopurinol 100 mg
 Ascorbic acid 500 mg
Q24H
 Aspirin 81 mg Q24H
 Carbidopa/entaca-
pone/levodopa QID
(Stalevo)
 Diclofenac topical BID,
PRN for pain
 Duloxetine 60 mg
Q24Ha
 Ergocalciferol
 Estradiol 1 mg Q24H
 Fluoxetine 10 mg
Q24Ha
 Furosemide
 Levocetirizine 5 mg
 Levothyroxine
75 mcg Q24H
 Lisinopril 20mgQ24H
 Multivitamin Q24H
 Olopatadine nasal BID
 Omeprazole 40 mg
Q24H
 Potassium chloride
10 mEq BID
 Ropinirole TID
 Rosuvastatin Q48H
 Ubiquinone 300 mg
Q24H
a Warning for serotonin syndrome.hospital course was uneventful. The patient was discharged on
hospital day 7 to a rehabilitation facility.Discussion
Methylene blue (MB) is a MAOI utilized during surgical
procedures as a dye or vasopressor demonstrated in the litera-
ture to cause SS in high risk patients. The primary risk factor is
present use of serotonergic medications. Age is an independent
risk factor as elderly patients are more likely to be on anti-
depressant medications.2 There are 31 cases of SS reported in
literature following MB administration during para-
thyroidectomies used for visualization of parathyroid tissue.3
There are also cases reported after cardiac surgery where MB
is used to treat vasoplegic syndrome.4 While most cases resolve,
Top et al reports a fatal case of SS.5 In 2011 the FDA issued a
warning regarding the use of MB in patients on psychiatric
medications, however incidences of SS continue to appear in
literature.6,7 MB is also used during pelvic and abdominal sur-
geries to identify potential injury to the ureters or bladder.8
However, only two of these cases were reported and there was
no case speciﬁc to urology.9,10
The diagnosis of SS was evaluated with Sternbach’s and
Hunter’s criteria (Table 1). Our patient was at risk due to her
serotonergic medications: ﬂuoxetine and duloxetine. She pre-
sented with four clinical features of serotonin toxicity: mental
status change (restlessness and confusion), agitation, diaphoresis,
and fever. This met Sternbach’s criteria, which only required three.
Other etiologies such as malignant hyperthermia (MH), neuro-
leptic malignant syndrome (NMS), and infection were ruled out.
She did not meet Hunter’s criteria though, which emphasized the
presence of clonus.1 Whereas Hunter’s criteria had better sensi-
tivity than Sternbach’s criteria (84% vs 75%), they have similar
speciﬁcity (97% and 96% respectively). The high speciﬁcity of both
criteria yields a high positive predictive value, hence a low false
positive rate.
Evaluation of ureteral patency, injury, or identifying the ure-
teral oriﬁces is common practice during urological surgeries ac-
cording to the American Urological Association guidelines.11
Urologists often times use marker dyes to identify ureteral in-
juries, and MB should be used with caution. Other options include
indocyanine green and indigo carmine. However, indocyanine
green has not been studied for cystoscopy and indigo carmine is
no longer readily available due to national supply shortages.12
There have been recent studies looking at alternatives for intra-
operative cystoscopy. Phenazopyridine (given orally preopera-
tively) and sodium ﬂuorescein are other agents used to visualize
bilateral ureteral jets.13
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The shortage of indigo carmine has increased the usage of al-
ternatives including MB in urology, which in tandem with the in-
crease in patients on psychiatric mediations, heightens the risk of
SS. It is therefore important to raise awareness about this drug
interaction within the urological ﬁeld. It is strongly recommended
that physicians take the necessary precautions before utilizing MB
on patients on serotonergic medications.
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